Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal
The Pharma Data
JANUARY 5, 2021
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. The first identifies the 3D RNA motifs.
52 
Let's personalize your content